iRadimed (IRMD)
(Delayed Data from NSDQ)
$42.50 USD
0.00 (0.00%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $42.23 -0.27 (-0.64%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IRMD 42.50 0.00(0.00%)
Will IRMD be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for IRMD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IRMD
Acadia Healthcare (ACHC) Opens Facility to Serve California
UnitedHealth (UNH) Unit Awarded a Medicaid Contract by AHCCCS
IRMD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Centene's (CNC) Ambetter Enhances Offerings With Broward Health
Centene (CNC) Wins Contract From Arizona's Medicaid Agency
5 Small Hidden Gems for the Rest of 2023
Other News for IRMD
iRadimed management to meet with Lake Street
IRADIMED CORPORATION Announces Uplisting to The Nasdaq Global Market
Iradimed uplists to Nasdaq Global Market
Iradimed Advances to Nasdaq Global Market Status
iRadimed announces uplisting to The Nasdaq Global Market